Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
My experience with Zenopa has been great. They were welcoming, efficient, respectful of me and my time and set my expectations well in terms of which roles I could get.
Jivan, 2012

Bristol-Myers Squibb licenses cancer drug from Innate Pharma

7 July 2011 00:00 in Pharmaceutical Company Product News


Bristol-Myers Squibb has announced a new global licensing deal that will allow it to develop and commercialise a new cancer compound created by Innate Pharma.

The agreement pertains to the developmental therapy IPH102, a potential first-in-class biologic that functions by blocking KIR receptors.

It is currently in phase I clinical testing and will continue to be developed by Innate Pharma as an acute myeloid leukaemia therapy until the end of phase II, with Bristol-Myers Squibb to offer its support.

The agreement will see Bristol-Myers Squibb pay an upfront fee of $35 million (21.9 million pounds) for rights to the drug, plus additional payments of up to $430 million based on clinical and commercial milestones.

Francis Cuss, senior vice-president of research at Bristol-Myers Squibb, said: "Bristol-Myers Squibb is dedicated to helping patients prevail over cancer."

Last month, the company partnered with Roche to investigate a new treatment option for metastatic melanoma that combines two of the firms' existing cancer drugs.ADNFCR-8000103-ID-800614330-ADNFCR

Other news stories from 07/07/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd